Guidelines Development Group

The objective of the Guidelines Development Group (GDG) is to develop evidence-based European Guidelines for breast cancer screening and diagnosis for screening and diagnosis.

The GDG will follow the GRADE approach in defining the healthcare question of interest (population of interest, interventions to be compared and patient-relevant outcomes- PICO), synthesizing the evidence and developing the recommendations for the Guidelines. This will be carried out within virtual working environments and in meetings organised every three months.

An external contractor, CCIb –Iberoamerican Cochrane Centre, supports the GDG for their tasks from literature review to drafting of recommendations.

Members and external experts

Cecily Quinn

Cecily Quinn

GDG clinical vice-chair

Cecily Quinn MB (hons), MD, FRCPI, FRCPath, FFPath is a Consultant Histopathologist at St. Vincent’s University Hospital and Senior Clinical Lecturer at UCD School of Medicine and Medical Sciences.

She is Lead Histopathologist at the Merrion Unit of the Irish National Breast Screening Programme.

She is also the RCPI National Specialty Director in Histopathology and represented histopathology on the RCPI Imrie and Keane review committees.

Dr Quinn graduated from University College Galway in 1982. She trained at the Hammersmith Hospital and Royal Postgraduate Medical School in London and was Consultant Breast Histopathologist at The General Infirmary at Leeds and Honorary Senior Lecturer at the University of Leeds until 1999 when she took up her present post.

Dr Quinn is a member of the Irish National Quality Assurance Breast Screening Committee and is the histopathology representative on the Breast Symptomatic Lead Clinicians Group.

She attends the UK (NHS) Breast External Quality Assurance Committee and is Chair of the European Working Group for Breast Screening Pathology.

Her main research interests are the pathology of early neoplastic lesions of the breast, and prognostic and predictive markers in invasive breast disease.

She has 60 publications in peer-reviewed journals.

She is a member of the HER2 and Triple Negative Research Group at St. Vincent’s University Hospital and the Translational Oncology Group at UCD.

She is a member of the International Editorial Advisory Board of Histopathology and a committee member of the Pathological Society of Great Britain and Ireland.

Declaration of interests